Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients

American Heart Journal

Volumn 198, Issue , 2018, Pages 4-17

  Cacoub, Patrice ^a   Nahon, Pierre ^a,b   Layese, Richard ^a   Blaise, Lorraine ^a   Desbois, Anne Claire ^a   Bourcier, Valérie ^a   Cagnot, Carole ^a   Marcellin, Patrick ^a,c   Guyader, Dominique ^a,d   Pol, Stanislas ^a,e   Larrey, Dominique ^a,f   De Lédinghen, Victor ^a,g   Ouzan, Denis ^a,h   Zoulim, Fabien ^a,i   Roulot, Dominique ^a,j   Tran, Albert ^a,k   Bronowicki, Jean Pierre ^a,l   Zarski, Jean Pierre ^a,m   Riachi, Ghassan ^a,n   Calès, Paul ^a,o   Péron, Jean Marie ^a,p   Alric, Laurent ^a,q   Bourlière, Marc ^a,r   Mathurin, Philippe ^a,s   Blanc, Jean Frédéric ^a,t   Abergel, Armand ^a,u   Serfaty, Lawrence ^a,v   Mallat, Ariane ^a,w   Grangé, Jean Didier ^a,x   Attali, Pierre ^a,y   Bacq, Yannick ^a,z   Wartelle, Claire ^a,aa   Dao, Thông ^a,ab   Thabut, Dominique ^a   Pilette, Christophe ^a,ad   Silvain, Christine ^a,ae   Christidis, Christos ^a,af   Capron, Dominique ^a,ag   Thiefin, Gérard ^a,ah   Zucman, David ^a   Di Martino, Vincent ^a,aj   Bagnis, Corinne Isnard ^a   Ziol, Marianne ^a   Sutton, Angela ^a   Letouze, Eric ^a   Roudot Thoraval, Françoise ^a   Audureau, Etienne ^a   Fontaine, Hélène ^e   Leroy, Vincent ^m   Dharancy, Sebastien ^s   Benhamou, Yves ^ac   Hillaire, Sophie ^ai   more..

^a Université Paris 5 ^*

^b UNIVERSITÉ PARIS 13   (France)

^c BEAUJON HOSPITAL   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e Institut Cochin   (France)

^f HÔPITAL SAINT ELOI   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h INSTITUT ARNAULT TZANCK   (France)

ⁱ HÔTEL DIEU   (France)

^j AVICENNE HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF NICE   (France)

^l CHU NANCY BRABOIS   (France)

^m HÔPITAL MICHALLON   (France)

ⁿ HÔPITAL CHARLES NICOLLE   (France)

^o ANGERS UNIVERSITY HOSPITAL   (France)

^p CHU PURPAN   (France)

^q TOULOUSE UNIVERSITY HOSPITAL   (France)

^r HÔPITAL SAINT JOSEPH   (France)

^s LILLE UNIVERSITY HOSPITAL   (France)

^t HÔPITAL SAINT ANDRÉ   (France)

^u HÔTEL DIEU   (France)

^v HÔPITAL SAINT ANTOINE   (France)

^w HENRI MONDOR HOSPITAL   (France)

^x HÔPITAL TENON   (France)

^y HÔPITAL PAUL BROUSSE   (France)

^z SERVICE DE DERMATOLOGIE   (France)

^aa Hôpital d'Aix en Provence   (France)

^ab CHU CÔTE DE NACRE   (France)

^ac ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^ad CHU du Mans   (France)

^ae POITIERS UNIVERSITY HOSPITAL   (France)

^af INSTITUT MUTUALISTE MONTSOURIS   (France)

^ag AMIENS UNIVERSITY HOSPITAL   (France)

^ah SERVICE DE DERMATOLOGIE   (France)

^ai FOCH HOSPITAL   (France)

^aj UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; SERUM ALBUMIN; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; ASIAN; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; LIVER FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET COUNT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; SUSTAINED VIROLOGIC RESPONSE; VIRAL CLEARANCE; AGE DISTRIBUTION; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMPLICATION; FRANCE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO; VIROLOGY;

AGE DISTRIBUTION; AGED; ANTIVIRAL AGENTS; BIOPSY, NEEDLE; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FRANCE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 85041394783     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.10.024     Document Type: Article

References (51)

1. Cacoub, P., Poynard, T., Ghillani, P., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42:10 (1999), 2204–2212.
2. Cacoub, P., Gragnani, L., Comarmond, C., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 46:Suppl. 5 (2014), S165–173.
3. Negro, F., Forton, D., Craxì, A., et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149:6 (2015), 1345–1360.
4. Okuse, C., Yotsuyanagi, H., Koike, K., Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations. J Gastroenterol 42:11 (2007), 857–865.
5. Lee, M.-H., Yang, H.-I., Lu, S.-N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206:4 (2012), 469–477.
6. Matsumori, A., Matoba, Y., Sasayama, S., Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92:9 (1995), 2519–2525.
7. Vassalle, C., Masini, S., Bianchi, F., et al. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90:5 (2004), 565–566.
8. Ishizaka, N., Ishizaka, Y., Takahashi, E., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359:9301 (2002), 133–135.
9. Hsu, Y.-C., Ho, H.J., Huang, Y.-T., et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64:3 (2015), 495–503.
10. Tomiyama, H., Arai, T., Hirose, K., et al. Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity. Atherosclerosis 166:2 (2003), 401–403.
11. Guiltinan, A.M., Kaidarova, Z., Custer, B., et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 167:6 (2008), 743–750.
12. Domont, F., Cacoub, P., Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver Int 36:5 (2016), 621–627.
13. Vachiat, A., McCutcheon, K., Tsabedze, N., et al. HIV and ischemic heart disease. J Am Coll Cardiol 69:1 (2017), 73–82.
14. Nieto, F.J., Infections and atherosclerosis: new clues from an old hypothesis?. Am J Epidemiol 148:10 (1998), 937–948.
15. Sangiovanni, A., Prati, G.M., Fasani, P., The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43:6 (2006), 1303–1310.
16. Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. Lancet 385:9973 (2015), 1124–1135.
17. Innes, H.A., McDonald, S.A., Dillon, J.F., Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62 (2015), 355–364.
18. Brennan, T., Shrank, W., New expensive treatments for hepatitis C infection. JAMA 312 (2014), 593–594.
19. Saadoun, D., Thibault, V., Si Ahmed, S.N., et al. Sofosbuvir plus ribavirin for hepatitis C virus–associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 75:10 (2016), 1777–1782.
20. Gragnani, L., Visentini, M., Fognani, E., et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus–associated mixed cryoglobulinemia. Hepatology 64:5 (2016), 1473–1482.
21. Sise, M.E., Bloom, A.K., Wisocky, J., et al. Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63:2 (2016), 408–417.
22. Trinchet, J.C., Bourcier, V., Chaffaut, C., et al. Complications and competing risks of death in compensated viral cirrhosis. (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
23. Ganne-Carrié, N., Bourcier, V., Cagnot, C., et al. Nomogram for individualized prediction of hepatocellular occurrence in hepatitis C cirrhosis (ANRS CO12 CirVir). Hepatology 64:4 (2016), 1136–1147.
24. Nahon, P., Lescat, M., Layese, R., et al. Bacterial infection in compensated viral cirrhosis impairs 5year survival ANRS CO12 CirVir prospective cohort. Gut 66:2 (2017), 330–341.
25. Nahon, P., Bourcier, V., Layese, R., et al. Eradication of hepatitis infection in patients with cirrhosis reduces risk of liver and non liver complications. Gastroenterology, 152(1), 2017, 142-156.e2.
26. Von Elm, E., Altman, D.G., Egger, M., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
27. Setsirichok, D., Piroonratana, T., Assawamakin, A., et al. Small ancestry informative marker panels for complete classification between the original four HapMap populations. Int J Data Min Bioinform 6:6 (2012), 651–674.
28. Cacoub, P.P., Bhatt, D.L., Steg, P.G., et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 30:2 (2009), 192–201.
29. Sarrazin, C., Hezode, C., Zeuzem, S., et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 1:56 Suppl. 1 (2012), S88–100.
30. Yusuf, S., Hawken, S., Ounpuu, S., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:2004 (2004), 937–952.
31. Bongard, V., Cambou, J.P., Leizorovicz, A., Comparaison of cardiovascular factors and drug use in 14 544 french Patients with a history of myocardial infarction, ischemic stroke and / or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 11 (2004), 394–402.
32. Sabouret, P., Cacoub, P., Dallongeville, J., et al. Results for the French arm at baseline and one year. Arch Cardiovasc Dis 101:2 (2008), 81–88.
33. Petta, S., Maida, M., Macaluso, F.S., et al. Hepatitis infection is associated with increased cardiovascular mortality: of observational studies. Gastroenterology 150:1 (2016), 145–155.
34. Tsui, J.I., Whooley, M.A., Monto, A., et al. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail 15:5 (2009), 451–456.
35. Adinolfi, L.E., Zampino, R., Restivo, L., et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 20:13 (2014), 3410–3417.
36. Butt, A.A., Xiaoqiang, W., Budoff, M., et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 49:2 (2009), 225–232.
37. Pothineni, N.V.K.C., Delongchamp, R., Vallurupalli, S., et al. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol 114:12 (2014), 1841–1845.
38. Hsu, Y.-C., Lin, J.-T., Ho, H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59:4 (2014), 1293–1302.
39. Mostafa, A., Mohamed, M.K., Saeed, M., et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 59:8 (2010), 1135–1140.
40. Boddi, M., Abbate, R., Chellini, B., et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 47:1 (2010), 72–75.
41. Maruyama, S., Koda, M., Oyake, N., et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 58:1 (2013), 11–15.
42. Masia, M., López, N.C., Gutiérrez, F., et al. Treatment for hepatitis C virus with pegylated interferon plus ribavirin induces antiatherogenic effects on cardiovascular risk biomarkers in HIV infected and uninfected patients. J Antimicrob Chemother 66:8 (2011), 1861–1868.
43. Ishizaka, Y., Ishizaka, N., Takahashi, E., et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 67:1 (2003), 26–30.
44. Gupta, M., Brister, S., Is South Asian ethnicity an independent cardiovascular risk factor?. Can J Cardiol 22 (2006), 193–197.
45. Gupta, M., Singh, N., Verma, S., South Asians and cardiovascular risk: what clinicians should know. Circulation 113 (2006), e924–e929.
46. Rana, A., de Souza, R.J., Kandasamy, S., et al. Cardiovascular risk among South Asians living in Canada: a systematic review and meta-analysis. CMAJ Open 2 (2014), E183–E191.
47. Anand, S.S., Yusuf, S., Vuksan, V., et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 356 (2000), 279–284.
48. Li, Z.G., Wu, H., Zhou, Y.L., et al. Association of β-adrenergic receptor genes polymorphisms with incidence of subsequent cardiovascular events in Han Chinese patients with coronary artery disease. Chin Med J (Engl) 126:24 (2013), 4679–4684.
49. De Hoog, V.C., Lim, S.H., Bank, I.E., et al. Ethnic differences in clinical outcome of patients presenting to the emergency department with chest pain. Eur Heart J Acute Cardiovasc Care 5:7 (2016), 32–40.
50. Hoshide, S., Kario, K., Sierra, A., et al. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. Hypertension 66:4 (2015), 750–756.
51. Butt, A.A., Yan, P., Chew, K.W., et al. Risk of acute myocardial infarction among HCV+ and HCV− men at various lipid levels: results from ERCHIVES. Clin Infect Dis, 24, 2017 [Epub ahead of print].